Abstract
Introduction
Adolescent girls and young women (AGYW) in sub-Saharan Africa are disproportionately affected by the HIV epidemic and face an array of challenges using proven behavioral and biomedical prevention methods. To address the urgent need for expanding prevention options, we evaluated the baseline preferences of HIV prevention methods among participants enrolled in the MTN-034/REACH crossover trial along with their stated product preference prior to product initiation.
Methods
AGYW aged 16–21 years were enrolled at 4 study sites: Cape Town and Johannesburg, South Africa; Kampala, Uganda; and Harare, Zimbabwe and randomly assigned to the sequence of using oral PrEP and the dapivirine ring for 6 months each, followed by a choice period in which they could choose either product (or neither) for an additional six months. Eligible AGYW were HIV-negative, not pregnant and using effective contraception for at least two months prior to enrollment. Descriptive statistics were used to summarize demographic and behavioral data while multinomial analysis was used to determine predictors of stated product preference (ring or oral PrEP).
Results
Of the 247 AGYW enrolled in REACH, 34% were aged 16–17 and 89% had a primary partner.The median age of sexual debut was 16 years and 40% had ever been pregnant. At screening, 35% of participants were diagnosed with a sexually transmitted infection (STI), 39% had an AUDIT-C score associated with harmful drinking and 11% reported intimate partner violence in the past 6 months. Overall, 28% of participants, had CESD-10 scores suggestive of depressive symptoms (≥12) in the past week. At baseline, similar proportions stated a preference for the ring and oral PrEP (38.1% and 40.5% respectively), with 19% of participants stating they preferred both products equally. Only study site was significantly associated with product preference (P<0.05) with AGYW from Johannesburg having higher odds of preferring the ring and those from Kampala having higher odds of preferring both options equally.
Conclusions
We successfully enrolled African AGYW with a clear unmet need for HIV prevention. The balanced preference between the two products suggests that multiple biomedical prevention options may be appealing to this age group and could address their prevention needs.
Funder
National Institute of Allergy and Infectious Diseases
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute of Mental Health
National Institute of Health
Publisher
Public Library of Science (PLoS)
Reference50 articles.
1. Global HIV & AIDS statistics — 2020 fact sheet https://www.unaids.org/en/resources/fact-sheet - Accessed on November 20, 2021
2. UNAIDS. Women and HIV: a spotlight on adolescent girls and young women. UNAIDS. 2019. https://www.unaids.org/en/resources/documents/2019/women-and-hiv Accessed on November 20, 2021
3. Prevention of HIV in adolescent girls and young women: key to an AIDS-free generation;QA Karim;JAIDS Journal of Acquired Immune Deficiency Syndromes,2017
4. Adolescent girls and young women: key populations for HIV epidemic control;RC Dellar;Journal of the International AIDS Society,2015
5. Gilead Sciences, Inc. U.S. Food and Drug Administration Approves Gilead’s Truvada for Reducing the Risk of Acquiring HIV (Press Release). July 16, 2012. http://www.gilead.com/news/press-releases/2012/7/us-food-and-drugadministration-approves-gileads-truvada-for-reducing-the-risk-of-acquiring-hiv.)
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献